Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 96, Issue 3, Pages 483-497Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2015.07.007
Keywords
Second-line; Chemotherapy; Pancreatic cancer; Trials; Systematic review
Categories
Funding
- Sydney Catalyst
- National Health and Medical Research Council
- Pancare
- Cancer Institute NSW Career Development Fellowship
- Philip Hemstritch Fellowship
- Cancer Institute NSW Translational Program [10/TPG/1-04]
- Cancer Research UK [17263] Funding Source: researchfish
Ask authors/readers for more resources
There remains uncertainty regarding the optimal second-line chemotherapy in advanced pancreatic ductal adenocarcinoma (PDAC). The current recommendation of 5-fluorouracil and oxaliplatin may not be relevant in current practice, as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) has become a more popular first line therapy in fit patients. The majority of studies in this setting are single-arm Phase II trials with significant heterogeneity of patient populations, treatments and outcomes. In this review, we sought to systematically review and synthesise all prospective data available for the second-line treatment of advanced PDAC. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available